Skip to main content
Log in

Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Cortex and caudate specimens from human, non-human primate and rodent brains were examined for their ability to deaminate dopamine and for their sensitivity to irreversible monoamine oxidase (MAO) inhibitors. Using inhibition curves obtained with clorgyline, deprenyl and pargyline to estimate the relative proportions of MAO-A and MAO-B activity, dopamine was found to be deaminated predominantly by MAO-A in rat cortex and caudate. In contrast, dopamine was primarily an MAO-B substrate in human and vervet cortex and caudate. When clorgyline inhibition curves with tyramine or dopamine as substrate were compared in human, vervet and rat cortex, more pronounced species differences were found with dopamine than with tyramine. In all three species caudate tended to be more sensitive to inhibition by low concentrations of clorgyline than was cortex, suggesting a higher proportion of MAO-A activity in caudate. Similar species differences were also found when MAO-A activities were estimated using serotonin (5-HT): β-phenylethylamine (PEA) ratios (5-HT/5-HT + PEA). These ratios with selective substrates were highly correlated with clorgyline inhibition curves obtained with tyramine as substrate across 29 brain regions and tissues from different rodent and primate species (r=0.85, P<0.001). Data from both the substrate ratios and the clorgyline inhibition curves confirmed the relative predominance of MAO-B activity in primate brain regions (70–85%) as compared to rat brain regions (45%). Smaller species differences were observed in liver. Species differences in the proportion of brain MAO-A and B activities and in the deamination of dopamine and other substrates for MAO may have important implications in regard to the widespread use of rodent rather than primate models in the study of biogenic amine metabolism and of drugs affecting amine function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the anti akinetic effect after l-Dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transmission 36:303–326

    Google Scholar 

  • Braestrup C, Andersen H, Randrup A (1975) The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur J Pharmacol 34:181–187

    Google Scholar 

  • Campbell IC, Robinson DS, Lovenberg W, Murphy DL (1979) The effects of chronic regimens of clorgyline and pargyline on monoamine metabolism in the rat brain. J Neurochem 32:49–55

    Google Scholar 

  • Cross AJ, Glover V, Lofthouse R, Owen F (1978) Some observations on human brain monoamine oxidase. Proc of the B.P.S. Br J Pharmacol 63(3):408

    Google Scholar 

  • Demarest KT, Azzaro AJ (1979) The association of type A monoamine oxidase with the nigrostriatal dopamine neuron. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 423–430

    Google Scholar 

  • Donnelly CH, Murphy DL (1977) Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem Pharmacol 26:853–858

    Google Scholar 

  • Donnelly CH, Richelson E, Murphy DL (1976) Properties of monoamine oxidase in mouse neuroblastoma N1E-115 cells. Biochem Pharmacol 25:1639–1643

    Google Scholar 

  • Edwards DJ, Malsbury CW (1978) Characteristics of monoamine oxidases in brain and other organs of the golden hamster. Biochem Pharmacol 27:959–963

    Google Scholar 

  • Fowler CJ, Callingham BA, Mantle TJ, Tipton KF (1978) Monoamine oxidase A and B: A useful concept? Biochem Pharmacol 27:97–101

    Google Scholar 

  • Garrick NA, Redmond DE, Jr, Murphy DL (1979) Primate-rodent monoamine oxidase differences. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 351–359

    Google Scholar 

  • Glover V, Sandler M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265:80–81

    Google Scholar 

  • Hagen P, Weiner N (1959) Enzymatic oxidation of pharmacologically active amines. Fed Proc 18:1005–1012

    Google Scholar 

  • Hall DWR, Logan BW, Parsons GH (1969) Further studies on the inhibition of monoamine oxidase by M+B 9302 (clorgyline). Biochem Pharmacol 18:1447–1454

    Google Scholar 

  • Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285–1297

    Google Scholar 

  • Keane PE, Chanoine F, Strolin Benedetti M (1979) The effects of specific type A and B MAO inhibitors on reserpine-induced changes in brain dopamine and serum prolactin levels in the rat. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 341–346

    Google Scholar 

  • Kinemuchi H, Wakui Y, Toyoshima Y, Hayashi N, Kamijo K (1979) β-Phenylethylamine (PEA), a concentration-dependent preferential substrate for multiple forms of MAO. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 205–212

    Google Scholar 

  • Koenig JFR, Klippel RA: (1963) The rat brain. A stereotaxic atlas of the forebrain and lower parts of the brain stem. Baltimore: Williams and Wilkins

    Google Scholar 

  • Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275

    Google Scholar 

  • Major LF, Murphy DL, Lipper S, Gordon E (1979) Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine and serotonin in human cerebrospinal fluid. J Neurochem 32:229–231

    Google Scholar 

  • Murphy DL (1978) Substrate-selective monoamine oxidases: Inhibitor, tissue, species and functional differences. Biochem Pharmacol 27:1889–1893

    Google Scholar 

  • Murphy DL, Donnelly CH, Richelson E (1976) Substrate and inhibitor-related characteristics of monoamine oxidase in C6 rat glial cells. J Neurochem 26:1231–1235

    Google Scholar 

  • Murphy DL, Lipper S, Campbell IC, Major LF, Slater SL, Buchsbaum MS (1979) Comparative studies of MAO-A and MAO-B inhibitors in man. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 457–475

    Google Scholar 

  • Murphy DL, Redmond DE, Jr, Garrick N, Baulu J (1979) Brain region differences and some characteristics of monoamine oxidase type A and B activities in the vervet monkey. Neurochem Res 4:53–62

    Google Scholar 

  • Oommen A, Balasubramanian AS (1977) Studies on the monoamine oxidase of monkey brain. J Neurochem 28:645–654

    Google Scholar 

  • Owen F, Cross AJ, Lofthouse R, Glover V (1979) Distribution and inhibition characteristics of human brain monoamine oxidase. Biochem Pharmacol 28:1077–1080

    Google Scholar 

  • Robinson DS, Lovenberg W, Keiser H, Sjoerdsma J (1968) Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochem Pharmacol 17:109–119

    Google Scholar 

  • Roth JA, Feor K (1978) Deamination of dopamine and its 3-0-methylated derivative by human brain monoamine oxidase. Biochem Pharmacol 27:1606–1608

    Google Scholar 

  • Squires RF (1972) Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: A comparison of eight mammalian species. Adv Biochem Psychopharmacol 5:355–370

    Google Scholar 

  • Suzuki O, Katsumata Y, Oya M (1979) Characterization of some biogenic monoamines as substrates for type A and type B monoamine oxidase. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 197–204

    Google Scholar 

  • Waldmeier PC, Delini-Stula A, Maitre L (1976) Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 292:9–14

    Google Scholar 

  • White HL, Glassman AT (1977) Multiple binding sites of human brain and liver monoamine oxidase: Substrate specificities, selective inhibitions, and attempts to separate enzyme forms. J Neurochem 29:987–997

    Google Scholar 

  • Yang H-Y T, Neff NH (1974) The monoamine oxidases of brain: Selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 189:733–740

    Google Scholar 

  • Youdim MBH, Riederer P, Birkmayer W, Mendlewicz J (1979) The functional activity of monoamine oxidase: The use of deprenyl in the treatment of Parkinson's disease and depressive illness. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 477–496

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garrick, N.A., Murphy, D.L. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology 72, 27–33 (1980). https://doi.org/10.1007/BF00433804

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00433804

Key words

Navigation